



Formulation and Evaluation Oral Dispersible Tablets of Vibegron

G. Nagaraju^{1*}, V. Sirisha², Kavati Ramakrishna³, and Hareesh Dara¹

¹Department of Pharmaceutical Chemistry, Dhanvanthari Institute of Pharmaceutical Sciences, Sujathanagar, Kothagudem.

¹Department of Pharmaceutics, Sree College of Pharmacy, Nayakulagudem, Kothagudem, Telangana.

²Department of Pharmaceutics, Dhanvanthari Institute of Pharmaceutical Sciences, Sujathanagar, Kothagudem.

³Department of Pharmaceutics, Pulipati Prasad College of Pharmacy, Khammam.

Received: 12 Jan 2019 / Accepted: 8 Mar 2019 / Published online: 1 Apr 2019

Corresponding Author Email: gdp413@gmail.com

Abstract

In the present work, taste masking of Vibegron was carried out by using strong cation exchange resin tulsion 344. These taste-masked complexes were further formulated into the Oro dispersible tablet by the direct compression method using Ac-Di-Sol and Avicel as a super disintegrant. Vibegron is used in treating OAB symptoms. This thesis has described the production of a taste masked dosage form from initial determination of threshold bitterness concentration of the pure drug through to the development of a final taste masked prototype formulation. An attempt has been made in the current work to use cation exchange resins (Indion 234 and Tulsion-344) which is used in the long drug therapy of AIDS and Vibegron used to treat overactive bladder, a common problem in geriatric patients. It was found that the taste masked 1:2 ratio of LMV: HP- β -CD inclusion complex increases the bulk of final ODT blend (above 1000 mg) which is not feasible for formulation of ODTs. So in this study the ODTs of LMV: HP- β -CD inclusion complex (1:1 ratio) showing acceptable bitterness in human taste panel studies was used in formulation of ODTs. In all formulations, the dispersion produced was soft (without grittiness) with a good mouth feel, and the bitter taste was fully masked. *In vitro* drug release profile of all optimized ODT formulations showed around 90% of drugs release within 10 to 15 minutes in acidic buffer (pH 1.2), implying that the drug will be absorbed fast, increasing the chances of bioavailability. A three-month stability analysis was carried out. For the optimized formulations, there was no noticeable difference in time disintegration, hardness, friability, or drug content

Keywords

Vibegron, super disintegrant, Orodispersible

INTRODUCTION:

Oral is the most preferred route of drug administration but is not suitable for patients with dysphagia. To overcome this problem oral dispersible tablets is one of the famous technological innovations in the contract manufacturing and

pharmaceutical field. Taste masking and taste assessment are the two main factors taken into consideration while formulating ODTs as they disintegrate and/ or dissolves in oral cavities. Taste masking in addition is related to patient compliance.

Patient compliance is particularly important in pediatrics, geriatric and long drug therapy patients. An ODT is a drug dosage form available for a small variety of over the counter (OTC) and prescription drugs (4). ODT disintegrates and/ or dissolves rapidly in the mouth without the need for water, which makes it suitable during traveling without immediate access to water. Since swallowing the saliva containing the dissolved or dispersed medication, the drug is consumed normally. Any drugs in ODT are showing fast onset of action and improved bioavailability as compared to same drugs in traditional tablet dosage form. This is due to ODTs pregastric absorption. ODT is also the best formulation option for drugs with a first-pass effect.

METHODS:

Formulation of ODTs of Vibegron- Tulsion 344 Complex.

170 mg tablet was prepared by using drug-resin complex equivalent to 25mg of Vibegron. Microcrystalline cellulose (Avicel PH 101) and mannitol were used as diluents and croscarmellose as super disintegrant. Aspartame, strawberry flavor, menthol, aerosil were mixed at the end and three formulations viz. F1 to F3 of Vibegron:Tulsion 344 complex were prepared by using Croscarmellose sodium in 6.0%, 8.0%, and 10.0% concentration.

Table 1: Formulation of ODTs of Vibegron:Tulsion 344 Complex

Ingredients (Quantity in mg.)	F1	F2	F3
Resinate (Equivalent to 25mg of Vibegron)	76.50	76.50	76.50
Mannitol (Perreck-M)	45.57	42.17	38.77
Microcrystalline cellulose (Avicel PH 101)	30.36	30.36	30.36
Croscarmellose Sodium (Ac-Di-Sol)	10.20	13.60	17.00
Aerosil	0.625	0.625	0.625
Menthol	3.125	3.125	3.125
Aspartame	0.50	0.50	0.50
Strawberry Flavor	3.125	3.125	3.125
Tablet Weight	170	170	170

RESULTS AND DISCUSSION:

Taste Masking Assessment of Drug-Polymer Complexes

Sensory Test for Determination of Threshold Bitterness Concentration for Vibegron Six healthy human volunteers (of age group 20-25 years) held 10

ml of most dilute solution of Vibegron from 25, 50, 75, 100, 200, 225, and 250 µg/ml prepared in Phosphate Buffer pH 6.8, in their mouths for 10 seconds and washed their mouth with 50 ml distilled water. The bitter threshold concentration was judged by considering opinion of volunteers.

Table 1: Sensory Test for Determination of Threshold Bitterness Concentration for Vibegron

No. of volunteer	Concentration (µg/ml)						
	25	50	75	100	125	150	200
1	0	0	0	0	1	2	3
2	0	0	0	0	1	2	3
3	0	0	0	1	1	2	4
4	0	0	0	0	2	2	3
5	0	0	0	0	1	2	3
6	0	0	0	0	2	2	3

In vitro taste masking evaluation of Vibegron: tulsion 344 (1:1) complex

Table 2: In vitro taste masking evaluation of Vibegron: tulsion 344 (1:1) complex in phosphate buffer pH 6.8.

Time (sec.)	Concentration (µg/ml)			
	1	2	3	Average
30	52.65	53.56	53.75	53.32
60	64.57	63.96	64.78	64.51
120	80.64	81.12	80.75	80.83

Threshold Bitterness Concentration for Vibegron was found to be 100 µg/ml *in vitro* release of Vibegron from DRC was 80.83 g/ml below threshold bitterness concentration i.e., 100 g/ml upto time period of 120 seconds.

In-vivo Taste Evaluation of Vibegron: tulsion 344 (1:1) complex

The panel of 10 members using time intensity method determined bitterness value. From this data

it was observed that for up to 5 minutes, all volunteers have experienced no bitter taste with Vibegron, which is complexed with Tulsion 344 in 1:2 ratio. Volunteers rated that (1:2) drug: Tulsion 344 as tasteless and agreeable. For both variables, descriptive statistics such as mean and standard deviation were computed. INSTAT programme was used to perform a paired t test. Value $P < 0.05$ has been considered as statistically significant level.

Table 3: In-vivo Taste Evaluation of Vibegron: tulsion 344 (1:1) complex.

Volunteers	Bitterness level after taste masking					
	10 sec	1 min	2 min	5 min	10 min	15 min
1	0	0	0	0	0	0
2	0	0	0	0	0	1
3	0	0	0	0	0	0
4	0	0	0	0	1	1
5	0	0	0	0	0	0
6	0	0	0	0	1	1
7	0	0	0	0	0	0
8	0	0	0	0	0	1
9	0	0	0	0	0	1
10	0	0	0	0	0	0

Table 4: Volunteers Opinion Test for Vibegron Before and After Taste Masking

Time (seconds)	Before taste masking	After taste masking
	Mean $\pm$ SD	Mean $\pm$ SD
10	2.3*** $\pm$ 0.58	0
60	3.3*** $\pm$ 0.48	0
120	3.4*** $\pm$ 0.51	0
300	3.8*** $\pm$ 0.42	0
600	3.8*** $\pm$ 0.32	0.2*** $\pm$ 0.63
900	4.0*** $\pm$ 0.0	0.5*** $\pm$ 0.84

Determination of Drug Content in the Drug-Polymer Complex

Drug content of Vibegron: tulsion 344 (1:2) complex.

Resinate so prepared by the batch process, was evaluated for the drug content. Amount of resinate

containing 25 mg of Vibegron was stirred with 50ml of acidic buffer (pH 1.2) till the entire drug was leached out. Then the Suspension was filtered, and further dilutions were made. The drug content was noted spectrometrically at 251nm using acidic buffer (pH 1.2) as blank.

Table 5: Drug content of Vibegron: tulsion 344 (1:2) complex

Name of Complex	Theoretical Conc. (mg)	Practical Conc. (mg)	% Drug Content
Vibegron : Tulsion 344 (1:2)	25	24.73 $\pm$ 0.11	98.92

Drug content of LMV: indion 234 (1:1.5) complex.

The resinate prepared (containing 10 mg of LMV) was subjected for evaluation of drug content and the data obtained is shown in Table 7. It was observed

that the practical concentration obtained was 9.91 $\pm$ 0.043 mg, which was almost 99.1 % of theoretical concentration that is 10 mg.

Table 6: Drug content of Vibegron: tulsion 344 (1:15) complex

Name of Complex	Theoretical Conc. (mg)	Practical Conc. (mg)	% Drug Content
Lamivudine: Indion 234	10	9.91 ± 0.043	99.1 %

Evaluation of Oro dispersible Tablets

Pre-Compression Studies

The directly compressible tablet blends were evaluated for pre-compression studies to determine their flow and compressibility (86).

Table 7: Micromeritic Properties of tablet blends containing optimized drug: polymer complexes (n= 3)

Property	Vibegron: Tulsion 344
Carr's Index (%)	12.8 ±1.34
Bulk Density (g/ml)	0.7843 ± 0.94
Angle of Repose (0)	27.540± 0.13

Post-Compression Studies

Table 8: Evaluation of ODTs of Vibegron:Tulsion 344 Complex

Test	F1	F2	F3
Weight variation test	170.0±1.4	170.4±1.2	170.2±1.6
Hardness (Kg/cm ²)	3.5±0.09	3.75±0.08	4.00±0.10
Friability (%)	0.84	0.80	0.72
Drug content (%)	100.8±0.20	100.6±0.56	99.90±0.10
Wetting time (Seconds)	45±1.00	37±1.53	30±2.00
Mouth feel	-	-	-
<i>In vivo</i> disintegration time (Seconds)	57±1.97	48±1.86	30±1.37
<i>In vitro</i> dispersion time (Seconds)	42±1.00	38±2.00	25±1.53

In vitro release profile of formulated tablets:

Dissolution test of tablets was performed using acidic buffer pH 1.2 with USP dissolution type II apparatus at 100 rpm and 37±0.5°C temperatures. Test sample (5 ml) was withdrawn at a particular time interval and replaced with fresh dissolution media

maintained at 37±0.5°C. The test sample was filtered through a membrane filter having size 0.45 µm and analyzed using UV spectrophotometer at λ_{max} values. This test was performed on successive three tablets and mean ± SD calculated.

Table 9: Dissolution data for formulation F1 to F3

Time (Min)	F1	F2	F3
0	0	0	0
1	11.06 ± 0.70	16.31 ± 0.61	27.56 ± 0.54
2	18.37 ± 0.91	25.90 ± 1.01	41.99 ± 0.95
3	20.72 ± 1.28	35.54 ± 1.24	58.76 ± 1.31
4	24.58 ± 1.54	43.74 ± 1.34	67.36 ± 1.54
5	31.47 ± 1.61	48.48 ± 1.51	77.75 ± 1.37
6	41.89 ± 1.34	64.49 ± 1.31	87.42 ± 1.67
7	48.87 ± 1.47	73.09 ± 2.03	100.9 ± 1.84
8	57.39 ± 1.34	86.74 ± 2.61	-
9	67.70 ± 1.41	100.9 ± 2.87	-
10	77.57 ± 2.04	-	-
11	92.99 ± 2.14	-	-
12	99.74 ± 2.24	-	-
13	100.6 ± 1.84	-	-




Figure 1: Dissolution profile for formulation F1, F2, F3

As dose is very small, maybe dissolving rapidly and the drug soluble in acidic condition. Due to the presence of excess exchangeable ions in the dissolution medium the resinate showed 90% to 100% release of drug in about 6 to 12 minutes. As dose is a very small drug released from the resinate may be dissolved rapidly and the drug soluble in acidic condition.

From the above formulations it was found that Formulations **F3** shows fast disintegration & fast dissolution of tablets than other formulations. So, this formulation was optimized for further studies. These formulations contain 10% Ac- Di-Sol as super disintegrant.

Accelerated Stability Studies of the Optimized ODTs.

Accelerated stability studies were carried out according to an International Conference on Harmonization (ICH) guidelines. The optimized formulations were placed in aluminum capped transparent glass vials for three months under storage conditions of $45^{\circ}\text{C} \pm 2^{\circ}\text{C}$ and $75\% \pm 5\%$. At the end of each month, these samples were removed and analyzed for post compression tests.

The stability analysis showed that all the formulations were physically stable when maintained at $45^{\circ}\text{C} \pm 2^{\circ}\text{C}$ and $75\% \pm 5\%$ RH for three months, with no major differences in the findings. (88).

Table 10: Effect of Stability Studies on ODTs Prepared by Using Vibegron:Tulsion 344 Resinate.

Parameters Evaluated	1st month		2nd month		3rd month	
	Storage Condition		Storage Condition		Storage Condition	
	$30 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{RH}$	$40 \pm 2^{\circ}\text{C} / 75 \pm 5\% \text{RH}$	$30 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{RH}$	$40 \pm 2^{\circ}\text{C} / 75 \pm 5\% \text{RH}$	$30 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{RH}$	$40 \pm 2^{\circ}\text{C} / 75 \pm 5\% \text{RH}$
Hardness (kg/cm^2)	3.2 ± 0.1	4.1 ± 0.16	3.2 ± 0.44	4.5 ± 0.16	3.9 ± 0.31	4.8 ± 0.16
Friability (%)	0.82	0.75	0.62	0.73	0.82	0.49
In Vitro						
Dispersion time (sec)	25 ± 0.17	29 ± 0.12	22 ± 0.11	26 ± 0.19	26 ± 0.26	30 ± 0.48
Drug content (%)	100.70 ± 0.10	99.42 ± 0.17	99.72 ± 0.35	98.30 ± 0.67	99.37 ± 0.25	99.36 ± 0.38

SUMMARY AND CONCLUSION

Oral is the most preferred route of drug administration but is not suitable for patients with dysphagia. To overcome this problem, Oro dispersible tablets is one of the famous technological innovations in the contract manufacturing and pharmaceutical field. Taste masking and taste assessment are the two main factors taken into consideration while formulating ODTs as they disintegrate and/ or dissolves in oral cavities. Taste masking in addition is related to patient compliance. Patient compliance is particularly important in pediatrics, geriatric and long drug therapy patients.

In the formulation of Oro dispersible tablets of taste-masked polymeric complexes, combinations of super disintegrants (separately and in different ratios) were used. The aim was to improve patient compliance and have a fast onset of action. In all formulations, the dispersion produced was soft (without grittiness) with a good mouth feel, and the bitter taste was fully masked.

The disintegration tests performed on all of these formulations revealed that tablets containing resinsates disintegrated faster than tablets containing cyclodextrin inclusion complexes, which could be due to the additional use of cation exchange resins as super disintegrants.

In vitro drug release profile of all optimized ODT formulations showed around 90% of drugs release within 10 to 15 minutes in acidic buffer (pH 1.2), implying that the drug will be absorbed fast, increasing the chances of bioavailability.

A three-month stability analysis was carried out. For the optimized formulations, there was no noticeable difference in disintegration time, hardness, friability, or drug content.

Overall, this study concludes that, taste-masked ODTs of the drugs Vibegron and Lamivudine not only improve patient compliance but also overcome neglected dysphagia associated with these two drug therapies. A greater understanding of patient compliance in any of the drug treatments will allow proper formulations to be developed which in turn will improve treatment outcomes.

BIBLIOGRAPHY:

1. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies. *Crit Rev Ther Drug Carrier Syst* [Internet]. 2004 [cited 2021 Feb 28];21(6):433–75. Available from: www.begellhouse.com
2. Kaushik D, Dureja H, Saini T. orally disintegrating tablets: An overview of melt-in mouth tablet technologies and techniques. *Tablets Capsul*. 2004;2(1):30–6.
3. Aguilar JE. New SeDeM-ODT expert system: an expert system for formulation of Oro dispersible tablets obtained by direct compression. In: *Formulation tools for pharmaceutical development* Published by Woodhead Publishing Limited, 2013 [Internet]. Woodhead Publishing Limited; p. 137–54. Available from: <http://dx.doi.org/10.1533/9781908818508.137>
4. Wikipedia [Internet]. [cited 2020 Jul 21]. Available from: https://en.wikipedia.org/wiki/Orally_disintegrating_tablet
5. Hesari Z, Shafiee A, Hooshfar S, Mobarra N, Mortazavi SA. Formulation and taste masking of ranitidine orally disintegrating tablet. *Iran J Pharm Res* [Internet]. 2016
6. Dey P, Maiti S. Orodispersible tablets: A new trend in drug delivery. *J Nat Sci Biol Med* [Internet]. 2010 [cited 2021 Feb 28];1(1):2–5. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217286/>
7. Guidance for Industry: Orally Disintegrating Tablets [Internet]. Office of Pharmaceutical Science in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration. 2008. Available from: <http://www.fda.gov/cder/guidance/index.htm>
8. Chazin, Howard D, MD, MBA, Director CO of GD. Challenges in Generic Drug Safety and Surveillance – Opportunities for Research.
9. Mahavir C, Amar M, Tanu G, Chhajed A, Shrivastava A. Formulation Development and Evaluation of Montelukast Sodium Orodispersible Tablets: A New Trend in Asthma Treatment. *Int J Pharm Res Sci* [Internet]. [cited 2021 Feb 28];1(2):127–39. Available from: https://www.academia.edu/download/53674748/Formulation_Development_and_Evaluation_o20170627-9828-1qd794t.pdf
10. Pankaj S, Ashish D, Dheerendra R, Yogendra R, Ramakant J KS. Formulate and evaluate orodispersible tablets of primaquine. *Indo Am J Pharm Res*. 2015;5(5):1625–32.
11. Kalyankar P, Panzade P, Lahoti S. Formulation design and optimization of orodispersible tablets of quetiapine fumarate by sublimation method. *Indian J Pharm Sci* [Internet]. 2015 [cited 2021 Feb 28];77(3):267–73. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502140/>
12. Ayyappan T, Poojitha C, T V. Preparation of efavirenz orodissolving tablets. *Bangladesh J Sci Ind Res* [Internet]. 2014 [cited 2021 Feb 28];49(3):173–80. Available from: <https://www.banglajol.info/index.php/bjsir/article/view/22131>
13. Gilca M, Dragos D. Extraoral Taste Receptor Discovery: New Light on Ayurvedic Pharmacology [Internet]. Vol. 2017, Evidence-based Complementary and Alternative Medicine. 2017 [cited 2021 Feb 28]. Available from: <https://www.hindawi.com/journals/ecam/2017/5435831/abs/>
14. Mennella J, Reed D, Roberts K, Mathew P, Mansfield C. Age-related differences in bitter taste and efficacy of bitter blockers. *PLoS One*. 2014 Jul 22;9(7).
15. Meyerhof W, Batram C, Kuhn C, Brockhoff A, Chudoba E, Bufe B, et al. The molecular receptive ranges of human TAS2R bitter taste receptors. *Chem Senses* [Internet]. 2009 [cited 2021 Feb 28];35(2):157–70. Available from: <https://academic.oup.com/chemse/article-abstract/35/2/157/485156>.
16. Wiener A, Shudler M, Levit A, Niv MY. BitterDB: A database of bitter compounds. *Nucleic Acids Res* [Internet]. 2012 [cited 2021 Feb 28];40(D1). Available from: <https://academic.oup.com/nar/article-abstract/40/D1/D413/2903400>
17. Fini A, Bergamante V, Ceschel GC, Ronchi C, de Moraes CAF. Fast dispersible/slow releasing ibuprofen tablets. *Eur J Pharm Biopharm* [Internet]. 2008 [cited 2021 Feb 28];69(1):335–41.
18. Rajput K, Patel K, Trivedi U. β -Cyclodextrin Production by Cyclodextrin Glucanotransferase from an Alkaliphile Microbacterium terrae KNR 9 Using Different Starch Substrates. *Biotechnol Res Int*. 2016;2016:1–7.